What do systematic reviews say?

Any anti‐osteoporotic drugs vs placebo

Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  RR 0.99 [0.98, 1]
  5 studies · 9054 participants
  Moderate

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 3.12 [1.87, 5.21]
  2 studies · 132 participants
  Low

Antibody vs other antibody (stratified by antibody type)

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Antibody (T cell) vs steroids

It is very uncertain whether antibody (T cell) changes treatment adverse events: fever, chill, or malaise after drug… compared with steroid (stratified by antibody type) (very low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 23.88 [5.1, 111.86]
  4 studies · 280 participants
  Very low